転移性乳がんの女性に対するトラスツズマブとカペシタビンの併用療法

基本情報

NCT ID

NCT00107393

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

75

治験依頼者名

National Cancer Institute (NCI)

概要

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving trastuzumab together with capecitabine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving trastuzumab together with capecitabine works in treating women with metastatic breast cancer.

対象疾患

介入

依頼者（Sponsor）

実施施設 (10)